[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biogen Inc (BIIB)

Biogen Inc (BIIB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES , June 11, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biogen Inc....

BIIB : 199.96 (+2.94%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

NEW YORK , June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact...

BIIB : 199.96 (+2.94%)
How Is Biogen’s Stock Performance Compared to Other Biotech Stocks?

Biogen has recently outperformed its industry peers, and analysts remain reasonably upbeat about the stock’s prospects.

IBB : 170.49 (+2.75%)
AMGN : 354.06 (+4.84%)
BIIB : 199.96 (+2.94%)
1 Cash-Producing Stock with Impressive Fundamentals and 2 We Find Risky

1 Cash-Producing Stock with Impressive Fundamentals and 2 We Find Risky

SAIA : 487.14 (+5.05%)
ORLY : 90.10 (-0.40%)
BIIB : 199.96 (+2.94%)
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES , June 8, 2026 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biogen Inc....

BIIB : 199.96 (+2.94%)
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or “the Company”) (NASDAQ:...

BIIB : 199.96 (+2.94%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

NEW YORK , June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact...

BIIB : 199.96 (+2.94%)
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

Designation is supported by an exploratory analysis from the Phase 1b study showing that some children with SMA previously treated with gene therapy who had suboptimal clinical status experienced slowing...

BIIB : 199.96 (+2.94%)
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

Steroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at lower...

UCB.BB : 271.000 (+2.50%)
BIIB : 199.96 (+2.94%)
Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 29.36 (+3.09%)
BIIB : 199.96 (+2.94%)

Barchart Exclusives

This AI Supplier Could Become More Valuable Than Investors Expect
Vertiv is proving that the biggest AI winners won't necessarily only be the companies making the chips. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.